Key result
Bivalent mRNA booster linked to ~78% XBB.1.5 neutralization at six months in healthcare workers.
Why the study?
Healthcare workers face an increased risk of SARS-CoV-2 exposure and infection, requiring monitoring of vaccine-induced humoral immune response over time.
Does a bivalent mRNA SARS-CoV-2 vaccine booster improve humoral immune response in healthcare workers over 6 months?
Population
494 HCW who received a bivalent mRNA SARS-CoV-2 booster
Comparison
Booster immunization vs baseline prior to vaccination
Design
Cohort study
Follow-up
6-month period
Authors
Loading...
May inform HCW booster timing; leaves open durability and clinical protection beyond 6 months.
Cohort (n=494)
Does a bivalent mRNA SARS-CoV-2 vaccine booster improve humoral immune response in healthcare workers over 6 months?
Absolute Event Rate: 77.8% vs 51.1%
Bivalent mRNA SARS-CoV-2 vaccine boosters elicit a strong initial antibody response that declines over 6 months, with the greatest relative benefit seen in individuals with lower baseline immunity.
Fedele et al. (2025) conducted a cohort in SARS-CoV-2 (n=494). Bivalent mRNA SARS-CoV-2 vaccine booster vs. Baseline (pre-vaccination) was evaluated on Neutralization against XBB.1.5 subvariant. A bivalent mRNA SARS-CoV-2 vaccine booster increased XBB.1.5 neutralization from 51.1% at baseline to 77.8% at six months in a subset of healthcare workers.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: